ReviewJournal of breast cancer2026
Meeting Highlights: The 11th Korean Breast Cancer Society Consensus Conference on Axillary Management in Early Breast Cancer.
Review in Journal of breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 11th Korean Breast Cancer Society (KBCS) Consensus Meeting was convened to discuss the current expert opinions and practice patterns regarding controversial issues in the axillary management of early breast cancer in Korea. Fifty-three multidisciplinary experts participated in the panel voting. The case-based questions addressed three major domains: 1) omission of sentinel lymph node biopsy (SLNB) in clinically node-negative disease, 2) management of sentinel lymph node (SLN) micrometastases after upfront surgery, and 3) axillary management after neoadjuvant chemotherapy (NAC) for biopsy-proven node-positive disease. The panelists showed a cautious attitude toward SLNB omission in relatively younger postmenopausal patients, even when the clinicopathologic features were consistent with contemporary de-escalation trials, whereas support for omission increased substantially in older low-risk patients. For SLN micrometastases after upfront surgery, completion of axillary lymph node dissection (ALND) is rarely supported, although opinions vary regarding the need for axillary radiotherapy. In the neoadjuvant setting, routine clip placement in biopsy-proven positive nodes has not yet been universally adopted. However, there is strong support for omitting ALND in patients who convert to a clinically node-negative status with negative SLNs after NAC. The management of residual nodal disease after NAC remains controversial, particularly in cases of residual macrometastasis. The 11th KBCS Consensus Meeting demonstrated broad acceptance of axillary surgical de-escalation in selected clinical scenarios, while highlighting a persistently uncertain area. These findings emphasize the need for individualized, multidisciplinary decision-making and further prospective evidence to refine the axillary management of early breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.